A Phase 3 interventional study of exercise training and Adherence measures in Chronic Heart Failure, sponsored by University Medicine Greifswald. Recruiting at 1 site in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-12.
Sponsored by University Medicine Greifswald · Phase 3, Interventional, and Prevention
The aim of the study is I. To assess whether an individualized exercise training program is superior as compared to usual care with respect to exercise tolerance, II. to assess whether intervention tools that aim to increase exercise adherence are superior to an individualized exercise training alone with respect to exercise tolerance and long-term effects, and III. to identify biomarkers that that may be implemented into novel intervention tools aiming to increase exercise adherence in patients with chronic heart failure.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 120 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →University Medicine Greifswald is the lead sponsor of 149 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Usual car accruing to guidelines
Individualized exercise training program in addition to usual care
Behavioral: exercise training
Individualized exercise training plus measures to increase adherence
Behavioral: exercise training · Behavioral: Adherence measures
individualized exercise training
Measures to increase adherence to exercise training
VO2@AT
Change of cardiopulmonary exercise tolerance from baseline to 9 month follow-up measured by exercise testing: oxygen uptake at anaerobic threshold per kg body weight (METs)
Time frame: Month 9
Training adherence
Adherence to training sessions
Time frame: 9, 12, 18 and 24 month
AE
Adverse events, related and unrelated to exercise training
Time frame: 9, 12, 18 and 24 month
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medicine Greifswald